

Market Announcement

26 May 2026

Nexalis Therapeutics Ltd (ASX: NX1) – Suspension from Quotation

The securities of Nexalis Therapeutics Ltd ('NX1') will be suspended from quotation immediately under Listing Rule 17.2 at the request of NX1, pending the release of an announcement by NX1.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in NX1's request for voluntary suspension; or
- the release of the announcement to the market.

NX1's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Compliance

Melissa Kostopoulos
Senior Adviser – ASX Supervision
Australian Securities Exchange Limited
By Email: melissa.kostopoulos@asx.com.au
tradinghaltsmelbourne@asx.com.au

Request for voluntary suspension

Dear Melissa,

As announced on 22 May 2026, Nexalis Therapeutics Limited (ASX: NX1) ACN 611 845 820 (**Company**) requested a trading halt pending an announcement to the market regarding its existing debt funding facility (**Purpose**).

The Company advises it is currently yet not in a position to make this announcement and requests a voluntary suspension of its securities.

In accordance with ASX Listing Rule 17.2, the Company advises:

1. The voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the Purpose above.
2. The Company requests the voluntary suspension to remain in place until the earlier of commencement of normal trading on Thursday, 28 May 2026 or when the announcement regarding the Purpose is released to the market.
3. The Company expects to make the announcement regarding the Purpose to the market before the commencement of normal trading on Thursday, 28 May 2026.
4. The Company is not aware of any reason why the voluntary suspension should not be granted or of any other information necessary to inform the market about the voluntary suspension.

This request has been approved by the board of Nexalis Therapeutics Ltd.

Yours faithfully



James Barrie
Company Secretary